1. Introduction {#sec1}
===============

Hemophagocytic lymphohistiocytosis (HLH) is rare and life-threatening medical emergency \[[@B1]\]. Our patient is a middle-aged Chinese lady with alpha thalassaemia (HbH disease), presented to us with persistent fever and rapidly progressive pancytopaenia. She was eventually diagnosed with HLH triggered by parvovirus infection. She responded well to a course of high-dose steroid. To our knowledge, this is the first case of parvovirus-associated HLH in a patient with HbH disease.

2. Case Report {#sec2}
==============

Mdm A, a 36-year-old Chinese lady with alpha thalassaemia (HbH disease), presented to us with a one-week history of fever and chills. There was no localizing symptom of infection. Her physical examination findings were unremarkable.

Initial investigation ([Table 1](#tab1){ref-type="table"}) revealed pancytopaenia: hemoglobin (Hb) 7.3 g/dL (11--14.7 g/dL), white cell count (WC) 1.68 × 10^9^/L (3.37 to 8.38 × 10^9^/L), and platelet count 92 × 10^9^/L (172--378 × 10^9^/L). C-reactive protein was 24 while procalcitonin was 0.14. Renal function, liver enzymes, chest X-ray, and urinalysis were unremarkable.

She was given piperacillin-tazobactam empirically. Despite antibiotic, she remained febrile on day 3 of admission. Three sets of blood culture and urine culture were negative. Dengue NS 1 antigen was negative. Piperacillin-tazobactam was changed to carbapenem.

Computed tomography (CT) of the abdomen and pelvis was arranged to investigate the cause of fever. It showed hepatosplenomegaly but no intra-abdominal abscesses ([Figure 1](#fig1){ref-type="fig"}).

The pancytopaenia progressively worsened ([Table 2](#tab2){ref-type="table"}). Peripheral blood film showed marked leukopenia, thrombocytopenia, and significant anisopoikilocytosis with microcytosis and target and tear drop cells consistent with a picture of thalassaemia intermedia ([Figure 2](#fig2){ref-type="fig"}). A bone marrow examination was therefore performed. Typical bone marrow finding in a patient with HbH disease alone would reveal a hypercellular marrow with erythroid hyperplasia and marked dyserythropoiesis. Mdm. A\'s marrow however was hypocellular with decreased cell trails on the aspirate ([Figure 3](#fig3){ref-type="fig"}). There was marked erythroid hypoplasia with rare giant erythroblasts, and inclusion bodies were seen ([Figure 4](#fig4){ref-type="fig"}). There were also increased numbers of macrophages with active haemophagocytosis ([Figure 5](#fig5){ref-type="fig"}). There was no evidence of lymphoma on bone marrow examination. Haemophagocytosis is however not exclusive of HLH. It may also be present in critically ill patients. Mdm. A was diagnosed with HLH based on the fact that she fulfilled 5 out of the 9 diagnostic criteria of HLH used in the HLH 2004 trial: fever \>38.5°C, splenomegaly, peripheral blood cytopaenia, haemophagocytosis in marrow, and ferritin \>500 ng/ml.

She was then transferred to a tertiary hospital for further treatment. 16 mg of dexamethasone once daily was initiated. Dexamethasone dose was reduced by 50% every 5 days. After 5 days of 2 mg once daily dexamethasone, the steroid was stopped. She responded well to the 20-day course of dexamethasone. She was reviewed in the clinic once a week after discharge, and other than her baseline anaemia due to HbH disease, other cell lines have recovered. Parvovirus B19 PCR was noted to be positive during her clinic visit. Diagnosis of parvovirus-induced HLH was made. She remained well in the subsequent clinic follow-up.

3. Discussion {#sec3}
=============

HLH is a syndrome caused by increased immune response, excessive macrophage activation, and cytokine release that leads to multiorgan dysfunction \[[@B1], [@B2]\]. It can be primary (familial) or secondary (reactive) \[[@B1]\]. Primary HLH is due to genetic defect and is mainly seen in children \[[@B1]\]. Secondary HLH occurs in adults \[[@B1]\]. It can be triggered by infection, autoimmune disease, or malignancy \[[@B1]\]. Infection-associated HLH (IAHLH) is commonly associated with Epstein--Barr virus (EBV) and cytomegalovirus (CMV) \[[@B3]\]. Klebsiella, HIV, herpes simplex, adenovirus, and parasitic and fungal infections have been implicated \[[@B3]\]. A study in Japan found that 1% of IAHLH was caused by parvovirus \[[@B1]\].

Diagnosis of HLH is challenging as the clinical features are nonspecific and can be seen in other inflammatory conditions such as sepsis and malignancy \[[@B1]\]. Based on the HLH 2004 guideline, 5 out of the 8 clinical criteria must be met for the diagnosis to be made \[[@B1]\]. They are as follows \[[@B1]\]:Fever \>38.5°CSplenomegalyCytopaenia (at least 2 cell lineages are affected)HypertriglyceridaemiaFerritin \>500 ng/mlHaemophagocytosis in bone marrow, spleen, or lymph nodesLow or absent natural killer (NK) cell activityElevated interleukin (IL) 2 receptor

The last two markers mentioned above are not available in Singapore. A ferritin level of \>10,000 ng/L was reported to have 90% sensitivity and 96% specificity for HLH \[[@B1]\]. A higher ferritin level was reported to reflect poorer prognosis and is therefore used as a marker to monitor treatment \[[@B1]\]. Haemophagocytosis in the marrow is not specific for HLH \[[@B1]\]. It can also be seen in haematologic malignancies or EBV infection \[[@B1]\]. Haemophagocytosis can be absent in HLH \[[@B1], [@B4]\]. Its sensitivity is 80--83%, and specificity is 60% \[[@B1]\].

Kio et al. described a case of sickle cell crisis associated with HLH \[[@B5]\]. The patient recovered without immunosuppression \[[@B5]\]. They mentioned that some cytokines implicated in HLH like IL-6, IL-2R, and TNF-alpha are raised in sickle cell disease \[[@B5]\]. Moreover, zinc deficiency which is common in sickle cell disease and thalassaemia major is related to impaired NK-cell activity and HLH pathogenesis \[[@B5]\]. We however found no prior report on HLH in HbH disease. We believe that the same pathogenesis applied in our case.

HLH treatment consists of dexamethasone and etoposide \[[@B1]\]. Our patient responded well to a 20-day course of dexamethasone without etoposide. Yuan et al. \[[@B1]\] have also reported a case of B19-related IAHLH that responded well to dexamethasone monotherapy previously. Immunoglobulin has been used with success in some cases \[[@B2], [@B6]\].

HLH is fatal if left untreated \[[@B1]\]. Median survival of \<2 months and mortality of 58--75% were described \[[@B1]\]. EBV-associated IAHLH carries high mortality while B19 infection related IAHLH has better prognosis \[[@B2]\]. Hereditary spherocytosis is the most common underlying disease in B19-associated HLH \[[@B2]\]. We believe that HbH, being a chronic haemolytic anaemia, may also have increased susceptibility for B19 infection. It appears important to perform an extensive workup for the infectious aetiology of HLH as management and prognosis may be different \[[@B2]\].

In conclusion, HLH is a life-threatening and complex clinical syndrome that has nonspecific clinical findings. High degree of suspicion is required for early diagnosis. Prompt treatment of the underlying aetiology combined with immunosuppressant seems to be ideal treatment. HbH, being a haemolytic anaemia, may have increased risk of getting B19-related HLH. More prospective studies are required to identify the treatment and outcome of B19-related HLH.

Additional Points
=================

\(1\) A multidisciplinary approach by experienced clinicians including haematologists and infectious disease specialists is required in the management of the patient. (2) A combination of high fever unresponsive to broad-spectrum antibiotics, hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, cytopaenia, and organomegaly are key diagnostic clues. (3) Bone marrow biopsy should be obtained to confirm diagnosis. (4) Thalassaemia intermedia (HbH disease) classically has increased erythroid precursors on bone marrow examination. Pure red cell aplasia as demonstrated by rare giant erythroblasts with inclusion bodies on bone marrow examination is highly suggestive of a parvovirus B19 infection suppressing erythrocytosis. Parvovirus B19 serology should be done to confirm this if available.
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![Computed tomographic coronal section showing hepatosplenomegaly.](CRIM2018-8057045.001){#fig1}

![Marked anisopoikilocytosis with microcytosis. Teardrop cells, target cells, and contracted red blood cells can be seen. Leukopenia and thrombocytopenia are present.](CRIM2018-8057045.002){#fig2}

![Hypocellular marrow fragment for age with decreased cell trails.](CRIM2018-8057045.003){#fig3}

![(a, b) Giant erythroblasts with inclusion bodies dwarfing the granulocyte precursors.](CRIM2018-8057045.004){#fig4}

![Haemosiderin-laden macrophage with active haemophagocytosis of an RBC.](CRIM2018-8057045.005){#fig5}

###### 

Values of relevant laboratory tests on presentation.

  Test                                        Results    Unit         Reference interval
  ------------------------------------------- ---------- ------------ --------------------
  White blood cell                            1.68       ×10^9^/L     3.40--9.60
  Hemoglobin                                  7.3        g/dL         11.5--15.1
  Mean cell volume                            58.4       fL           80.0--95.0
  Mean corpuscular hemoglobin concentration   18.6       g/dL         32.0--36.0
  Platelets                                   92                      132--372
  Creatinine                                  56         mg/dL        0.6--1.0
  Urea                                        2.5        mg/dL        5.6--18.2
  Albumin                                     47         g/dL         3.8--4.8
  Bilirubin, total                            31         mg/dL        0.3--1.8
  Aspartae aminotransferase                   41         U/L          11--34
  Alanine aminotransferase                    19         U/L          10--36
  Alkaline phosphatase                        43         U/L          40--130
  Prothrombin time                            11.5       Seconds      9.2--11.4
  Beta-hcg (serum)                            Negative                 
  Vitamin B12                                 363        Nmol/l       7--37
  Folate                                      33         Pmol/l       145--569
  Serum iron                                  37.7       Umol/Litre   6.6--30.4
  Ferritin                                    944        Ng/ml        13--150
  Iron saturation                             84                      15--150
  Fibrinogen                                  3.06       g\\L         1.8--3.5
  Total iron binding capacity                 45         Umol/Litre   52--94
  Haptoglobin                                 38         mg/dL        30--200
  Triglycerides                               1.49       Mmol/l       1.7--2.2

###### 

Blood investigations on Day 1, Day 2, and Day 3 of hospitalisation.

  Labs                        Day 1   Day 2   Day 3
  --------------------------- ------- ------- -------
  Total white cell count      1.68    0.92    0.61
  Absolute neutrophil count   0.98    0.59    0.25
  Hemoglobin                  7.3     6.1     5.2
  Platelets                   92      65      58
  Ferritin                    944             2536
  Bilirubin                   31              22
  AST                         41              83
  ALT                         19              53
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